Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
about
CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine
P2860
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Early circulating tumor DNA dy ...... fulvestrant for breast cancer.
@en
Early circulating tumor DNA dy ...... fulvestrant for breast cancer.
@nl
type
label
Early circulating tumor DNA dy ...... fulvestrant for breast cancer.
@en
Early circulating tumor DNA dy ...... fulvestrant for breast cancer.
@nl
prefLabel
Early circulating tumor DNA dy ...... fulvestrant for breast cancer.
@en
Early circulating tumor DNA dy ...... fulvestrant for breast cancer.
@nl
P2093
P2860
P1476
Early circulating tumor DNA dy ...... fulvestrant for breast cancer
@en
P2093
Charlotte Fribbens
Cynthia Huang Bartlett
Isaac Garcia-Murillas
James P Morden
Maria Koehler
Massimo Cristofanilli
Matthew Beaney
Nicholas C Turner
Sarah Hrebien
P2860
P2888
P356
10.1038/S41467-018-03215-X
P407
P577
2018-03-01T00:00:00Z